ASSESSMENT OF ADVERSE DRUG REACTIONS ON CARDIOVASCULAR DRUGS IN HOSPITALIZED PATIENTS OF A TERTIARY CARE HOSPITAL – A PROSPECTIVE ANALYSIS
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i10.45583Keywords:
Adverse drug reaction, Severity, Treatment, Inpatients, PreventabilityAbstract
Objective: The present study was taken up to assess the adverse drug reactions (ADRs) based on the spontaneous reactions among the inpatients who were hospitalized for the treatment of cardiac ailments.
Methods: A prospective and observational study was done in the department of cardiology for a period of 6 months. Patients on cardiac drug therapy were evaluated to detect unwanted effects and were given treatment for the developed complications. The ADRs were identified, followed up, and documented.
Results: In the present study, 255 inpatients were assessed to pinpoint the negative effects and about 80 (n=80) sufferers were recognized with 28 types of ADRs. The highest percentage of ADRs was in adults of age group 60–70 years. Type A accounted for most of the reports which was based on severity. The number of ADRs in heart muscle disorders was found to be 44% (n=35) followed by coronary artery disease 40% (n=32), then heart valve disorders and patients underwent surgery were affiliated to 8% (n=6) each. The highest number of ADRs was reported in patients suffered from disorders pertained to heart muscle. Majority of ADRs were rated as possible, preventable, and moderate according to causality, preventability, and severity parameters, respectively. The data were tabulated, analyzed, and subjected to statistics using Graph Pad Prism 8.
Conclusion: It was concluded that proper management and monitoring of drug therapy are the key to prevent ADRs.
Downloads
References
Gupta M, Kharb P, Kalaiselvan V, Shridhar M, Singh GN, Kshirsagar N, et al. Safety of medicines: Pharmacovigilance programme of India. WHO Drug Inform 2018;32:10-7.
WHO Media Centre. Fact Sheet: Cardiovascular Diseases (CVDs); 2016. Available from: https://www.who.int/mediacentre/factsheets/ fs317/en [Last accessed on 2016 Oct 27].
Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E. Pharmacovigilance: Pharmacists’ perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract 2017;6:91-8. doi: 10.2147/IPRP.S105881
Siddarama R, Bharath Naidu J, Joshisree KP, Sahithi Lakshmi V. Polypharmacy induced drug interactions, adverse drug reactions (ADR) and medication errors in tertiary care south Indian hospital. Int J Pharm Pharm Sci 2019;11:83-93.
Sriram S, Ghasemi A, Ramasamy R, Devi M, Balasubramanian R, Ravi TK, et al. Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci 2011;16:16-25.
Zaki SA. Adverse drug reaction and causality assessment scales. Lung India 2011;28:152-3. doi: 10.4103/0970-2113.80343
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. doi: 10.1038/clpt.1981.154
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32. doi: 10.1093/ajhp/49.9.2229
Kalaiselvan V, Srivastava S, Singh A, Gupta S. Pharmacovigilance in India: Present scenario and future challenges. Drug Safety 2019;42:339- 46. doi: 10.1007/s40264-018-0730-7
Shah R, Parajuli SB, Pokharel S. Knowledge of adverse drug reactions reporting among doctors and nurses in a tertiary care hospital: A descriptive cross-sectional study. JNMA J Nepal Med Assoc 2021;59:22-5. doi: 10.31729/jnma.5386
Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J 2014;22:83-94. doi: 10.1016/j.jsps.2013.02.003
Gholami K, Ziaie S, Shalviri G. Adverse drug reactions induced by cardiovascular drugs in outpatients. Pharm Pract (Granda) 2008;6:51-5. doi: 10.4321/S1886-36552008000100008
Kaur S, Kapoor V, Mahajan R, Lal M, Gupta S. Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease. Indian J Pharmacol 2011;43:22-6. doi: 10.4103/0253-7613.75661
Kaur S, Kapoor V, Mahajan R, Lal M, Gupta S. Patterns of ADRs and risk factors involved: Study in cardiology unit of an Indian tertiary care center. Indian J Pharmacol 2010;8:1. doi: 10.5580/2196
Kamejaliya DZ, Kapadia JD, Desai CK, Desai MK. An intensive monitoring of adverse drug reactions among elderly patients hospitalized in medical wards of a tertiary care hospital. J Young Pharm 2017;9:598-604. doi: 10.5530/jyp.2017.9.114
Wadhwa T, El Sheikh SG, Rao PG. Monitoring and reporting of adverse drug reactions due to cardiovascular drugs in patients admitted to a secondary care hospital in Northern Emirate-a prospective surveillance study. Indian J Pharm Pract 2018;11:71-8. doi: 10.5530/ ijopp.11.2.16
Danekhu K, Shrestha S, Aryal S, Shankar PR. Health-care professionals’ knowledge and perception of adverse drug reaction reporting and pharmacovigilance in a tertiary care teaching hospital of Nepal. Hosp Pharm 2021;56:178-86. doi: 10.1177/0018578719883796, PMID 34024926, PMCID PMC8114297
Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579-89. doi: 10.1016/S1470-2045(18)30608-9
Mugosa S, Bukumiric Z, Kovacevic A, Boskovic A, Protic D, Todorovic Z. Adverse drug reactions in hospitalized cardiac patients: Characteristics and risk factors. Vojnosanit Pregl 2015;72:975-81. doi: 10.2298/vsp140710104m
Published
How to Cite
Issue
Section
Copyright (c) 2022 sailaja rao
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
